Pancreatic Cancer Research

ResearcherGuangzhou Medical UniversityActive in the last 2 years

Jie‐Qin Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3343-5639; OpenAlex author ID A5103283141. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
12
Papers, trials and grants by year

2020: 2 papers · 2021: none · 2022: none · 2023: 1 paper · 2024: 4 papers · 2025: none · 2026: 1 paper

Papers 8

  1. Synergistic Induction of Ferroptosis by GPX4 Inhibitor and GSH-Depleted Nanoparticles Effectively Reverses Gemcitabine Resistance in Pancreatic Ductal Adenocar… Co-author DOI 10.1002/adhm.202503694↗
  2. Epigenetic Activation of the CMTM6-IGF2BP1-EP300 Positive Feedback Loop Drives Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.202406714↗
  3. Platelet-Derived Growth Factor C Facilitates Malignant Behavior of Pancreatic Ductal Adenocarcinoma by Regulating SREBP1 Mediated Lipid Metabolism. Co-author DOI 10.1002/advs.202407069↗
  4. CSNK2A1 confers gemcitabine resistance to pancreatic ductal adenocarcinoma via inducing autophagy. Co-author DOI 10.1016/j.canlet.2024.216640↗
  5. N6-methyladenosine modified TGFB2 triggers lipid metabolism reprogramming to confer pancreatic ductal adenocarcinoma gemcitabine resistance. Co-author DOI 10.1038/s41388-024-03092-3↗
  6. Imatinib facilitates gemcitabine sensitivity by targeting epigenetically activated PDGFC signaling in pancreatic cancer. Co-author DOI 10.1016/j.ymthe.2022.11.004↗
  7. Targeting Super-Enhancers via Nanoparticle-Facilitated BRD4 and CDK7 Inhibitors Synergistically Suppresses Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1002/advs.201902926↗
  8. Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy. Co-author DOI 10.1039/d0nr03138k↗

Closest collaborators

The 12 strongest of 12 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xi‐Tai Huang · 7 shared papers, 2020–2026 · strength 1.24
  2. Xiao-Yu Yin · 5 shared papers, 2024–2026 · strength 1.04
  3. Yin-Hao Shi · 5 shared papers, 2023–2024 · strength 0.92
  4. Ying‐Qin Zhu · 5 shared papers, 2023–2024 · strength 0.92
  5. Zhide Liu · 5 shared papers, 2023–2024 · strength 0.92
  6. Chen‐Song Huang · 5 shared papers, 2020–2026 · strength 0.84
  7. Mingjian Ma · 4 shared papers, 2024 · strength 0.75
  8. Xiaoyu Yin · 3 shared papers, 2020–2023 · strength 0.36
  9. Wei Zhao · 2 shared papers, 2020–2024 · strength 0.28
  10. Yue Huang · 1 shared paper, 2024 · strength 0.18
  11. Qi Liu · 1 shared paper, 2023 · strength 0.16
  12. Liying Wang · 1 shared paper, 2020 · strength 0.10

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.